NCT07849166Completed
BRCC36 and Telomerase Levels in Women With Polycystic Ovary Syndrome
Evaluation of Serum BRCC36 and Telomerase Levels in Women With Polycystic Ovary Syndrome
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
This prospective observational case-control study evaluated serum BRCC36 and telomerase (TE) levels in women with polycystic ovary syndrome (PCOS) and healthy controls. Women aged 18-43 years were included. The study comprised 30 women diagnosed with PCOS according to ESHRE/ASRM criteria and 30 healthy women with regular menstrual cycles. A single 5-mL venous blood sample was collected from each participant. Serum was separated by centrifugation and stored at -80°C until analysis. Serum BRCC36 and telomerase levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits. The study evaluated differences in these biomarkers between women with PCOS and healthy controls and their relationships with clinical and biochemical characteristics.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 60 (actual)
- First submitted
- 24 Sept 2026
- Start date
- 20 Feb 2024
- Primary completion date
- 20 Feb 2025
- Lead sponsor
- Cumhuriyet University
- NCT number
- NCT07849166
What you commit to
- Study type: Observational
- Participants enrolled: 60
- From 20 Feb 2024 to the primary completion date, 20 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications affecting sex hormone or carbohydrate metabolism.
Other illness
- Thyroid dysfunction, prolactinoma, Cushing disease, or late-onset congenital adrenal hyperplasia.
- Diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, or renal or hepatic dysfunction.
- Additional gynecological disease.
Lab values
- Inadequate or unsuitable blood/serum sample for laboratory analysis.
Who the study is looking for
- Women aged 18-43 years.
- PCOS group: diagnosis of PCOS according to ESHRE/ASRM criteria, based on the presence of at least two of the following: oligo- and/or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology.
- Control group: healthy women with regular menstrual cycles (21-35 days), modified Ferriman-Gallwey score \<8, and no unilateral or bilateral polycystic ovarian morphology on pelvic ultrasonography.
- BMI \<30 kg/m².
- No oral contraceptive use during the study period or within the previous 6 months.
- Written informed consent.
Age in the registry: 18 years to 43 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sivas Cumhuriyet University Coordinator of this site? Confirm its status | Sivas | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.